Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?

CRISPR Therapeutics' Casgevy, a gene therapy for sickle cell disease and transfusion-dependent beta-thalassemia developed with Vertex Pharmaceuticals, has seen modest initial commercial uptake with only $10 million in 2024 sales despite being the first CRISPR-based therapy; this is attributed to the complex treatment process, while Vertex is expanding treatment center availability and anticipates significant patient growth in 2025, CRISPR faces competition from Beam Therapeutics' BEAM-101 and existing therapies from Bristol Myers and Novartis, with CRISPR Therapeutics' shares outperforming the industry year-to-date but loss per share estimates for 2025 and 2026 have widened.

Analysis

CRISPR Therapeutics' (CRSP) first commercial product, Casgevy, a gene therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) co-developed with Vertex Pharmaceuticals (VRTX), has experienced a modest initial commercial uptake. Vertex, which leads commercialization and records all product sales, reported only $10 million in Casgevy revenues for full-year 2024, reflecting the complexities of the treatment process involving stem cell collection, ex vivo gene editing, and reinfusion. Despite these hurdles and its high price of $2.2 million, Casgevy offers potential as a one-time functional cure for an estimated 60,000 eligible patients. Vertex is actively expanding its commercial infrastructure, having activated over 65 authorized treatment centers globally with nearly 90 patients initiating cell collection by May 1, and anticipates significant growth in new patient starts throughout 2025, with model estimates forecasting Casgevy sales of approximately $99 million for 2025. CRSP, which shares in Casgevy's profits/losses, faces competition from Beam Therapeutics' (BEAM) advancing CRISPR-based candidate BEAM-101, which has shown positive early data, and from established, lower-cost therapies such as Bristol Myers' (BMY) Reblozyl and Novartis' (NVS) Adakveo. While CRSP shares have outperformed the industry year-to-date and trade at a price-to-book ratio of 2.10, below the industry average of 3.04 and its own five-year mean of 2.39, investor caution is signaled by widening loss per share estimates for 2025 (to $5.54 from $5.06) and 2026 (to $4.30 from $3.76) over the past 60 days, contributing to its Zacks Rank #3 (Hold) and a slightly negative per-ticker sentiment (-0.2).

Key Decisions for Investors

• Investors should closely monitor Vertex's execution on Casgevy's commercial ramp-up, particularly the rate of new patient starts and progress towards the projected $99 million in 2025 sales, as this will be a key determinant of CRSP's share of profits and future valuation.
• It is crucial to evaluate the evolving competitive landscape, including clinical trial results and market penetration of Beam Therapeutics' BEAM-101 and the impact of significantly lower-priced existing treatments from Bristol Myers and Novartis on Casgevy's uptake, given its $2.2 million price point.
• Consider CRSP's discounted valuation (P/B 2.10) and recent stock outperformance in the context of widening loss per share estimates for 2025 and 2026, balancing the long-term disruptive potential of its gene-editing technology against near-term financial headwinds and commercialization challenges.